Articles
03.05.2022
What are the top 5 considerations to be aware of b...

Introduction: Brazil is a market of 210 million people Brazil is the largest country in South Americ...

Read more
Insider Insights
15.03.2022
NICE presents three-year international strategy

Two NICE teams (NICE International and the Science Policy and Research Programme) will act as key en...

Read more
Articles
10.03.2022
Orphan status higher prices in the UK

Beyond the regulatory level, a well-recognised challenge for companies launching drugs in orphan dis...

Read more
Articles
01.03.2022
China's most recent NRDL update

In December 2021, China once again updated its National Reimbursed Drugs List (NRDL).

Read more
Insider Insights
28.02.2022
UK first rare disease action plan

On 28th February 2022, Health and Social Care Secretary Sajid Javid launched England’s first Rare...

Read more
Articles
24.02.2022
Patient reported outcomes

This educational blog explores what PROs are, explains why they of growing importance in the digital...

Read more
Articles
07.02.2022
Advanced therapy medicinal product withdrawals

Advanced therapy medicinal products (ATMPs) are medicinal products for human use that are based on l...

Read more
Insider Insights
01.02.2022
New restrictions for Prolia

The study showed that 20 - 25% of all prescriptions for the drug were not in line with the drug's au...

Read more
Insider Insights
01.02.2022
Committee recommends rejecting Rx to non-Rx reques

The committee’s recommendations are forwarded to the Federal Ministry of Health for consideration.

Read more
Articles
01.02.2022
Changes to NICE's health technology evaluation

This reforms have been welcomed by the industry as they should support faster access to medicines as...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.